



## Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results

March 31, 2026

*Full Year 2025 record revenue of \$62.1 million*

ROMEDEVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the fourth quarter and year ended December 31, 2025.

"In 2025, we achieved record revenue of \$62.1 million, effectively doubling our line of consumer products in just two years. This affirmed both the value we bring to the industry, and our ability to establish ourselves as a leading innovator and manufacturer of SPF-infused beauty products," said Kevin Cureton, President and Chief Executive Officer.

"In November, we launched Transform & Transcend. This is a broad-based strategic initiative that is aligning our operational execution with the changes in our organization brought on by our rapid commercial growth, and subsequently enables our company to capitalize on the market position we have established and the intellectual property investments we have made. Transform & Transcend is built on four core pillars: operational excellence through lean management principles, technology-driven expansion of our addressable market, increasing our share of the value chain through service model innovation, and collaborative globalization through entering new geographies in cooperation with our brand partners. Through the methodical execution of this initiative, our organization will be positioned to deliver sustainable, profitable growth above the industry averages and long-term value for our shareholders."

Laura Riffner, Chief Financial Officer, noted, "We exited 2025 with strong momentum due in part to organizational changes and the start of the Transform and Transcend initiative. Looking ahead to 2026, we are confident in our ability to deliver against our full-year objectives."

### Summary Fourth Quarter 2025 Financial Results

#### Fourth Quarter Financial Highlights

- Revenue for the fourth quarter was \$12.5 million, compared to \$12.6 million for the same period in 2024.
- Gross profit increased to \$3.4 million in the fourth quarter, compared to \$2.8 million for the same period in 2024.
- Gross margin in the fourth quarter was 27%, compared to 22% for the same period in 2024.
- Net income in the fourth quarter was approximately \$0.2 million, compared to a net loss of approximately \$0.6 million for the same period in 2024.

### Summary Full Year 2025 Financial Results

- Revenue for the twelve months ended December 31, 2025, was a record \$62.1 million compared to \$52.3 million, a 19% increase over the same period in 2024.
- Gross profit for the twelve months ended December 31, 2025, was \$16.1 million compared to \$16.2 million over the same period in 2024.
- Gross margin for the twelve months ended December 31, 2025, was 26%, compared to 31% for same period in 2024.
- Net income for the twelve months ended December 31, 2025, was \$1.8 million compared to \$4.2 million in the same period in 2024.

### Recent Highlights

- Appointed Yoolie Park as Vice President of Brand Partnerships to drive commercialization strategy and further deepen and expand our relationships with our beauty brand partners.
- Acquired 20 new brand partners in facial skincare and color cosmetics.
- Expanded skin health patent protection through 16 U.S. and foreign patents across our technology platforms. This includes additional global patent protection for our award-winning Kleair™ technology; a skin health and healing technology that will be launching in 2026; and an emerging plant-based technology in our pipeline.

### Conference Call

Solésence will host its fourth quarter conference call on Tuesday, March 31, 2026 at 7:30 a.m. CT, 8:30 a.m. ET, to discuss its financial results and provide a business and financial update. On the call will be Kevin Cureton, President and Chief Executive Officer, and Laura Riffner, Chief Financial Officer.

Webcast Link: <https://edge.media-server.com/mmc/p/btv3gq6b>

Dial-In Link: <https://register-conf.media-server.com/register/BI2103cfa8634b4409927981d42999af41>

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

The call may also be accessed through the Company's investor relations website, at <https://ir.solesence.com/>. Please join the conference call at least five minutes prior to the start time.

## FINANCIAL RESULTS AND NON-GAAP INFORMATION

### Use of Non-GAAP Financial Information

Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles ("GAAP") and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

### About Solésence, Inc.

Solésence, Inc. (Nasdaq: SLSN), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at [solesence.com](https://solesence.com).

### Forward-Looking Statements

*This press release contains words such as "expects," "shall," "will," "believes," and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company's dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company's engineered materials, ingredients, and fully formulated products; the Company's manufacturing capacity and product mix flexibility in light of customer demand; the Company's limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company's dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company's Form 10-K filed March 31, 2026. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.*

### Media Contact:

[media@solesence.com](mailto:media@solesence.com)

### Investor Relations Contact:

[investors@solesence.com](mailto:investors@solesence.com)

**SOLÉSENCE, INC**  
**CONSOLIDATED BALANCE SHEETS**  
**(Unaudited Consolidated Condensed)**

|                           | (in thousands except share and<br>per share data) |                      |
|---------------------------|---|----------------------|
|                           | December 31,<br>2025                              | December 31,<br>2024 |
|                           | (Unaudited)                                       | (Unaudited)          |
| <b>ASSETS</b>             |   |                      |
| <b>Current assets:</b>    |   |                      |
| Cash                      | \$ 1,288  | \$ 1,409             |
| Trade accounts receivable | 7,642   | 5,655                |

|   |                  |                  |
|---|------------------|------------------|
| Allowance for credit losses               | (806)            | (786)            |
| Trade accounts receivable, net            | 6,836            | 4,869            |
| Inventories, net                          | 18,511           | 20,267           |
| Prepaid expenses and other current assets | 2,141            | 2,803            |
| Total current assets                      | <u>28,776</u>    | <u>29,348</u>    |
| Equipment and leasehold improvements, net | 14,329           | 12,734           |
| Operating leases, right of use            | 6,913            | 7,917            |
| Other assets, net                         | 37               | 3                |
| Total assets                              | <u>\$ 50,055</u> | <u>\$ 50,002</u> |

#### LIABILITIES AND STOCKHOLDERS' EQUITY

##### Current liabilities:

|   |               |               |
|---|---------------|---------------|
| Line of credit, accounts receivable, related party          | \$ 4,767      | \$ -          |
| Current portion of line of credit, inventory, related party | -             | 4,000         |
| Current portion of debt, related parties                    | -             | 1,000         |
| Current portion of operating lease obligations              | 1,255         | 1,260         |
| Accounts payable  | 4,098         | 9,093         |
| Deferred revenue  | 930           | 5,571         |
| Accrued expenses  | 2,879         | 4,849         |
| Total current liabilities                                   | <u>13,929</u> | <u>25,773</u> |

|   |               |              |
|---|---------------|--------------|
| Long-term portion of operating lease obligations              | 7,798         | 9,037        |
| Long-term portion of line of credit, inventory, related party | 9,500         | -            |
| Long-term portion of debt, related parties                    | 1,000         | -            |
| Asset retirement obligations                                  | 194           | 246          |
| Total long-term liabilities                                   | <u>18,492</u> | <u>9,283</u> |

##### Stockholders' equity:

|  |                  |                  |
|--|------------------|------------------|
| Preferred stock, \$.01 par value, 24,088 shares authorized and no shares issued and outstanding  | -                | -                |
| Common stock, \$.01 par value, 95,000,000 shares authorized; 70,614,045 and 70,103,279 shares issued and outstanding on December 31, 2025 and 2024, respectively | 706              | 700              |
| Additional paid-in capital   | 115,566          | 114,674          |
| Accumulated deficit  | (98,638)         | (100,428)        |
| Total stockholders' equity   | <u>17,634</u>    | <u>14,946</u>    |
| <b>Total liabilities and shareholders' equity</b>  | <u>\$ 50,055</u> | <u>\$ 50,002</u> |

**SOLÉSENCE, INC**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited Consolidated Condensed)  
(in thousands except share and per share data)

|                 | Three months ended<br>December 31, |               | Twelve months ended<br>December 31, |               |
|-----------------|------------------------------------|---------------|-------------------------------------|---------------|
|                 | 2025                               | 2024          | 2025                                | 2024          |
| <b>Revenue:</b> |                                    |               |                                     |               |
| Product revenue | \$ 12,425                          | \$ 12,411     | \$ 61,794                           | \$ 51,890     |
| Other revenue   | 58                                 | 156           | 270                                 | 457           |
| Net revenue     | <u>12,483</u>                      | <u>12,567</u> | <u>62,064</u>                       | <u>52,347</u> |
| Cost of revenue | <u>9,049</u>                       | <u>9,801</u>  | <u>46,001</u>                       | <u>36,159</u> |
| Gross profit    | 3,434                              | 2,766         | 16,063                              | 16,188        |

##### Operating expense:

|  |            |            |            |            |
|--|------------|------------|------------|------------|
| Research and development expense                               | 1,035      | 1,091      | 4,090      | 3,837      |
| Selling, general and administrative expense                    | 2,213      | 1,898      | 10,401     | 7,219      |
| Income (loss) from operations                                  | 186        | (223)      | 1,572      | 5,132      |
| Interest income  |            |            |            |            |
| Interest expense   | 328        | 108        | 931        | 670        |
| Other income, net  | (12)       | -          | 1,222      | -          |
| Income (loss) before provision for income taxes                | (154)      | (331)      | 1,863      | 4,462      |
| Provision for income taxes                                     | (317)      | 227        | 73         | 227        |
| Net income (loss)  | \$ 163     | \$ (558)   | \$ 1,790   | \$ 4,235   |
| Net income (loss) per share-basic                              | \$ -       | \$ (0.01)  | \$ 0.03    | \$ 0.07    |
| Weighted average number of common shares outstanding - basic   | 70,565,573 | 70,011,564 | 70,344,152 | 62,350,459 |
| Net income (loss) per share-diluted                            | \$ -       | \$ (0.01)  | \$ 0.02    | \$ 0.07    |
| Weighted average number of common shares outstanding - diluted | 72,808,204 | 70,011,564 | 72,579,715 | 65,028,815 |

**SOLÉSENCE, INC**  
**CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE**  
(Unaudited Consolidated Condensed)  
(in thousands except share and per share data)

|  | Three months ended<br>December 31, |           | Twelve months ended<br>December 31, |           |
|--|------------------------------------|-----------|-------------------------------------|-----------|
|  | 2025                               | 2024      | 2025                                | 2024      |
| <b>Revenue:</b>  |                                    |           |                                     |           |
| Product revenue  | \$ 12,425                          | \$ 12,411 | \$ 61,794                           | \$ 51,890 |
| Other revenue  | 58                                 | 156       | 270                                 | 457       |
| Net revenue  | 12,483                             | 12,567    | 62,064                              | 52,347    |
| <i>Cost of revenue detail:</i>                             |                                    |           |                                     |           |
| Depreciation   | 212                                | 218       | 861                                 | 881       |
| Non-Cash equity compensation                               | 39                                 | 44        | 112                                 | 124       |
| Other costs of revenue                                     | 8,798                              | 9,539     | 45,028                              | 35,154    |
| Cost of revenue  | 9,049                              | 9,801     | 46,001                              | 36,159    |
| Gross profit   | 3,434                              | 2,766     | 16,063                              | 16,188    |
| <b>Operating expense:</b>                                  |                                    |           |                                     |           |
| <i>Research and development expense detail:</i>            |                                    |           |                                     |           |
| Depreciation   | 3                                  | 4         | 14                                  | 21        |
| Non-Cash equity compensation                               | 43                                 | 53        | 139                                 | 152       |
| Other research and development expense                     | 989                                | 1,034     | 3,937                               | 3,664     |
| Research and development expense                           | 1,035                              | 1,091     | 4,090                               | 3,837     |
| <i>Selling, general and administrative expense detail:</i> |                                    |           |                                     |           |
| Depreciation and amortization                              | 5                                  | 6         | 22                                  | 26        |
| Non-Cash equity compensation                               | 125                                | 151       | 324                                 | 449       |
| Other selling, general and administrative expense          | 2,083                              | 1,741     | 10,055                              | 6,744     |
| Selling, general and administrative expense                | 2,213                              | 1,898     | 10,401                              | 7,219     |
| Income from operations                                     | 186                                | (223)     | 1,572                               | 5,132     |
| Interest income  |                                    |           |                                     |           |

|  |               |                 |                 |                 |
|--|---------------|-----------------|-----------------|-----------------|
| Interest expense                         | 328           | 108             | 931             | 670             |
| Other income, net                        | (12)          | -               | 1,222           | -               |
| Income before provision for income taxes | (154)         | (331)           | 1,863           | 4,462           |
| Provision for income taxes               | (317)         | 227             | 73              | 227             |
| Net income (loss)                        | <u>\$ 163</u> | <u>\$ (558)</u> | <u>\$ 1,790</u> | <u>\$ 4,235</u> |

Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):

|                                      |               |              |                 |                 |
|--------------------------------------|---------------|--------------|-----------------|-----------------|
| Addback Interest, net                | 328           | 108          | 931             | 670             |
| Addback Depreciation/Amortization    | 220           | 228          | 897             | 928             |
| Addback Non-Cash Equity Compensation | 207           | 248          | 575             | 725             |
| Subtract Non-Cash Other Income       | -             | -            | -               | -               |
| Adjusted EBITDA                      | <u>\$ 918</u> | <u>\$ 26</u> | <u>\$ 4,193</u> | <u>\$ 6,558</u> |